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Transthoracic echocardiography provides important long-term prognostic 
information in selected patients undergoing endovascular abdominal aortic 
repair. 
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Abstract 
 
Background The value of performing transthoracic echocardiography (TTE) as part of the 
clinical assessment of patients awaiting endovascular repair of the abdominal aorta (EVAR) 
is little evaluated. We aimed to estimate the prognostic importance of information derived 
from TTE on long-term all-cause mortality in a selected group of patients undergoing EVAR.  
 
Methods and Results This was a retrospective cohort study of 273 consecutive patients 
selected for EVAR. All patients included in analysis underwent TTE before their procedure. 
Multivariable Cox regression analysis was used to estimate the effect of TTE measures on 
all-cause mortality. Over a mean follow up of 3.2±1.5 years there were 78 deaths with a mean 
time to death of 1.28±1.16 years. A greater tubular ascending aorta (HR 5.6, 95% CI 2.77-
11.33), presence of mitral regurgitation (HR 8.13, 95% CI 4.09-12.16), lower left ventricular 
ejection fraction (HR 0.96, 95% CI 0.93-0.98), younger age (HR 0.97, 95% CI 0.95-0.99) and 
presence of diabetes (HR 1.46, 95% CI 1.24-1.89) were predictors of all-cause mortality. 
 
Conclusions Echocardiography provides important long-term prognostic information in 
patients undergoing EVAR. These TTE indices were more important at predicting outcome 
than standard conventional risk factors in this patient group. A greater tubular ascending 
aorta, presence of mitral regurgitation, reduced left ventricular ejection fraction, younger age 
and diabetes were independently associated with long-term mortality.  
 
Key words: Abdominal aortic aneurysm, Endovascular aneurysm repair, Transthoracic 
echocardiography.  
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Introduction 
 
Abdominal aortic aneurysms (AAA) remain a significant health challenge with a reported 
prevalence of 1.4% in the US, increasing significantly in males over the age of 60. 
Traditionally, surgical repair for AAA has consisted of an open operative approach requiring 
laparotomy with extensive associated morbidity and mortality. Endovascular aneurysm repair 
(EVAR) has developed into a viable alternative to open surgery for AAA repair and is now 
the predominant method of aneurysm repair in most developed nations.
1
  
 
Despite an established benefit in terms of peri-operative mortality for EVAR,
2, 3
 the long-
term outcome in patients with AAA, undergoing either open or endovascular surgery, 
remains poor.  Pre-existing data suggest that long-term survival is worse in patients surviving 
AAA repair than in an age-gender matched population,
4-6
 and that late mortality is 
predominantly attributable to cardiovascular causes.
7
 There is a strong association between 
traditional cardiovascular disease risk factors and higher incidence of AAA.
8, 9
 
 
Consensus guidelines recommend pre-operative risk stratification of patients with AAA to 
optimise patient care and prevent complications, including mortality.
10, 11
 Pre-operative 
cardiac assessment appears to be of most importance, since the most frequent complications 
post EVAR are cardiac.
12
 Risk prediction based on clinical risk factors alone have 
limitations
13
 and existing models for elective AAA repair fail to predict outcome with 
sufficient accuracy to be widely adopted into routine clinical practice.
14
 Consequently, 
physicians routinely request specialised cardiac tests to improve risk stratification. As such, a 
transthoracic echocardiogram (TTE) is often advised as part of the clinical assessment of 
patients awaiting aneurysm repair. This is despite the lack of evidence base. Peri-procedural 
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mortality for EVAR is very low but these patients are usually elderly with other 
comorbidities with a 5-year survival of 52%.
15
 The long-term prognostic value of TTE is 
unclear in the EVAR population. Therefore, the aim of this study was to assess pre-operative 
echocardiographic predictors of long-term all-cause mortality in patients undergoing EVAR.  
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Methods 
 
Study Cohort 
The study population consisted of 273 consecutive patients (73±10.7 years) undergoing 
elective EVAR between January 2008 and September 2010 from a single tertiary centre. 
Patients with ruptured aneurysms and trauma-related cases were excluded. All patients had a 
TTE and electrocardiogram (ECG) 4-weeks prior to their EVAR in the outpatient setting, as 
part of a global risk stratification protocol. Clinical characteristics were recorded at the time 
of TTE. This investigation conformed to the Declaration of Helsinki principles. All patients 
provided informed consent before testing and the local research ethics committee approved 
the study. 
 
Transthoracic Echocardiography Image Acquisition 
A full cross-sectional study was performed using a General Electric Vingmed System 7. All 
image acquisitions and measurements were performed as recommended by the American 
Society of Echocardiography (ASE).
16
 Left ventricular end diastolic diameter (LVEDD), LV 
end systolic diameter (LVESD), interventricular and LV posterior wall thickness at end 
diastole were measured from parasternal M mode recordings of the LV, with the cursor at the 
tips of the mitral valve leaflets. LV mass (LVM) was then calculated according to the ASE 
recommendations.
16
 LV fractional shortening was calculated from LVEDD and LVESD. LV 
ejection fraction (LVEF) was determined by the modified biplane Simpson’s rule, with 
measurements averaged over three cardiac cycles. The LV endocardial border was traced 
contiguously from one side of the mitral annulus to the other, excluding the papillary muscles 
and trabeculations. LV regional wall motion was analysed visually using the standard 17-
segment model for qualitative analysis and wall motion was scored on a 4-point scale (1 = 
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normal wall motion, 2 = hypokinesis, 3 = akinesis, and 4 = dyskinesis). The wall motion 
score index was calculated as an average of the individual wall motion scores of each 
visualised segment. For patients with poor endocardial border definition in 2 or more 
contiguous LV segments, the intravenous LV contrast agent SonoVue
®
 was used to ensure 
optimal LV border definition.  
 
Transmitral inflow was recorded using pulsed wave Doppler recordings at the mitral valve 
leaflet tips in the apical four-chamber view. Peak velocity of early filling (E), peak velocity 
of atrial filling (A), the E/A ratio and E deceleration time were measured. From pulsed wave 
real-time tissue Doppler images obtained in the four-chamber view, early diastolic (Ea) 
velocities were measured. LV filling pressure was estimated from the mitral E/Ea ratio.
17
 
Echocardiographic evaluation of the aorta was performed in the parasternal long-axis and 
suprasternal view with measures recorded at the aortic annulus, sinuses of Valsalva, 
sinotubular junction, tubular ascending aorta, aortic arch and descending aorta as 
recommended.
18
 Full quantitative and semi-quantitative assessment of valvular disease was 
performed.
19, 20
 Valve disease was then graded as none, mild, moderate or severe. Two 
accredited TTE imaging specialists retrospectively examined all TTE data in an 
echocardiography core laboratory. 
 
Electrocardiography 
A 12-lead ECG was recorded in the supine position prior to EVAR. All tracings were 
interpreted by a trained physician and coded on the basis of the Minnesota coding criteria.
21
 
Evidence of ischemia on ECG was defined as pathological Q waves, ST-segment depression, 
T wave inversion of any degree or left bundle branch block.
22
 Left ventricular hypertrophy 
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was defined according to Sokolow and Lyon voltage criteria.
23
 The ECG was graded as 
normal or pathological.     
 
Endovascular Aneurysm Repair 
All patients in this cohort were elective admissions for EVAR. Endografting was performed 
via percutaneous or surgical approaches to the femoral artery. The EVAR procedure was 
performed to an Institutional standard operating protocol and undertaken in a dedicated 
endovascular imaging suite under fluoroscopic guidance. The endografts employed were 
proprietary endografts predominantly from Cook
©
 Medical, or Medtronic. Post-operative 
follow-up consists of a 6-week, 12-week, 6-month and subsequent annual consultation with a 
vascular surgeon.  
  
Primary Outcome Measure 
The primary outcome measure was long-term mortality up to 5 years post-surgery. Patients 
were followed up from the date of their EVAR procedure through to December 2013 and 
censored at the time of death or at last known follow-up. Mortality data were established 
through interrogation of electronic hospital or general practitioner records, and through the 
national death registry.  
 
Statistical Analysis 
Continuous variables were expressed as mean±standard deviation and categorical variables as 
n (%). Multivariable adjusted Cox proportional hazard models were constructed to ascertain 
predictors of all-cause mortality. For model building, demographic, clinical history, 
medication, laboratory measures and echocardiographic parameters were evaluated for their 
association with mortality. Age and gender were included in all models. Forward stepwise 
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selection procedures were used to compare models for goodness-of-fit and a P-value <0.1 
was used for retention in the final model. The final multivariate model consisted of 11 
variables (see Supplementary Table 1 and Supplementary Figure 1 for model goodness of fit 
and discrimination selection). Hazard ratios (HR) and corresponding 95% confidence 
intervals (CI) are reported.  
 
Kaplan-Meier survival curves were constructed and compared using the log-rank test and a P 
value <0.05 was used to report statistical significance. The survival curves were stratified 
first according to the presence or absence of mitral regurgitation (MR) and, second, by 
patient risk profile (low, intermediate, or high-risk), which was calculated from the 
multivariable Cox model by splitting patients into three tertiles of predicted risk. Event rates 
were calculated and expressed as percentages per annum. All analyses were conducted using 
the statistical package for social sciences (SPSS 21 release version of SPSS for Windows; 
SPSS Inc., Chicago IL, USA). 
 
 
 
 
 
 
 
 
 
 
 
	 9	
Results 
 
Clinical Outcome 
The primary endpoint of all-cause mortality was observed in 78 (29%) patients during a mean 
follow-up period of 3.2±1.5 years, with a mean time to death of 1.28±1.16 years. The clinical 
characteristics of subjects survived versus all-cause mortality are shown in Table 1. There 
was one peri-operative death in a 91-year old patient who experienced a post-procedural 
lateral myocardial infarct, and nine deaths within 30-days post surgery (see Figure 1). 
 
During the study period 273 consecutive patients were evaluated using TTE imaging 18±7 
days prior to elective EVAR. Mean age was 73±10.7 years with a greater proportion of male 
patients (80%) in keeping with the recognised male-preponderance of AAA. The prevalence 
of hypertension, hypercholesterolaemia and diabetes were 77%, 53% and 13% respectively 
with 2% of patients having a prior history of coronary revascularisation and 5% a prior 
myocardial infarction. In addition, 13% patients had a prior cerebrovascular accident and 
36% had previous evidence of ischaemic heart disease. Seventy-four (27%) patients were 
current smokers and 126 (46%) ex-smokers with a combined pack year of 32.8±24.2. 72% of 
patients (196/273) were treated with one or more anti-platelet medication, 9% (25/273) were 
warfarinised and 82% (229/273) were taking lipid-lowering therapies. However, use of other 
cardio-protective medication, such as beta-blockers (35%, 95/273) and angiotensin 
converting enzyme inhibitors (28%, 76/273) was low (Table 1). 
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Transthoracic Echocardiography 
TTE was completed in all patients and the level of inter-observer agreement in reporting echo 
parameters between the two sonographers was K=0.89 (range 0.86-1.0). The TTE results for 
subjects survived versus all-cause mortality are shown in Table 2. Two hundred and thirteen 
patients (78%) had a LVEF reported within the normal range, 34 (12%) mildly impaired, 22 
(8%) moderately impaired and 4 (2%) severely impaired.  
 
Thirteen patients (5%) had a mildly dilated LV, 3 (1%) moderately dilated, 3 (1%) severely 
dilated and 254 (93%) had a normal LVEDD. Fifty-five patients (20%) had a mildly dilated 
left atrium (LA), 12 (4%) moderately dilated, 15 (6%) severely dilated and 191 (70%) had 
normal LA dimensions. Sixty-four patients (23%) had resting wall motion abnormalities, 86 
(32%) had aortic valve disease, 137 (50%) had mitral valve disease (101 mild MR and 36 
moderate/severe MR), 58 (21%) had tricuspid valve disease, and 22 (8%) had pulmonary 
valve disease. Four patients (1%) had a dilated aortic annulus, three patients (1%) had a 
dilated sinus of Valsalva, 36 patients (13%) had a dilated sinotubular junction, 80 patients 
(29%) had a dilated tubular ascending aorta, 26 patients (10%) had a dilated aortic arch, and 
17 patients (6%) had a dilated descending aorta.  
 
Electrocardiography 
The resting ECG was performed 14±5 days before EVAR and was reported as pathological in 
69 (25%) patients and signs of myocardial ischemia were found in 20 (7%) patients (Table 
2).  
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Analyses 
In unadjusted analysis, LV fractional shortening, LV ejection fraction, mitral E, pulmonary 
artery pressure, proportion of patients with a pulmonary artery pressure >35 mmHg, diameter 
of the aortic sinotubular junction, tubular ascending aorta, aortic arch, and presence of MR 
were parameters that significantly differed between survivors and non-survivors. Previous 
medical history and use of medication was broadly similar across all groups.  
 
The unadjusted Kaplan-Meier curves for the cumulative incidence of long-term all-cause 
mortality, dichotomized according to the presence or absence of MR and low, intermediate 
and high-risk patients are presented in Figure 2 and Figure 3 respectively. The differences 
amongst these curves were significant (P<0.001). The all-cause mortality event rate for 
patients with no MR was 3% per year, increasing to 15% for those with mild MR, 16% with 
moderate MR and peaking at 26% in those with severe MR. With each increased degree of 
MR, there was a stepwise increase in the cumulative mortality (log rank χ2 = 59.8; p<0.001). 
The all-cause mortality event rate for low risk patients was 1% per year, increasing to 8% for 
intermediate risk patients, and highest amongst those with high risk (16%). With each 
increased level of the co-morbidity index, there was a stepwise increase in the cumulative 
mortality attributable to co-morbid disease (log rank χ2 = 44.7; p<0.001). 
 
Following adjusted multivariable Cox regression, a greater tubular ascending aorta (HR 5.6, 
95% CI 2.77-11.33, p<0.001), presence of MR (HR 8.13, 95% CI 4.09-12.16, p<0.001), 
lower left ventricular ejection fraction (HR 0.96, 95% CI 0.93-0.98, p<0.001), younger age 
(HR 0.97, 95% CI 0.95-0.99, p=0.005) and presence of diabetes (HR 1.46, 95% CI 1.24-1.89, 
p=0.021) were predictors of all-cause mortality (Table 3). When MR severity was added to 
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the multivariable model, mild MR (HR 4.84, 95% CI 2.8-13.92, p=0.002) and 
moderate/severe MR (HR 7, 95% CI 3.52-13.92, p<0.001) were predictors of mortality.  
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Discussion 
 
This large observational study of selected patients undergoing elective EVAR has identified 
for the first time that parameters routinely measured on TTE are powerful predictors of long-
term survival. In this study, the presence of MR, a greater tubular ascending aorta, a reduced 
LVEF, younger age, and presence of diabetes were independently associated with long-term 
all-cause mortality.  
 
In keeping with previous studies,
24
 peri-operative mortality was low in our study (1/273) with 
a 30-day mortality figure of 3%. As such, the use of TTE for peri-operative evaluation alone 
for patients undergoing elective EVAR is weak and this is supported by recent American 
Society of Echocardiography guidelines.
25
 Long-term mortality within the current study was 
similar to previous research.
15
 
 
One important finding is that MR when graded according to published guidelines
20
 is a 
powerful predictor of clinical outcome. Indeed, the prognostic power superseded all other 
predictive parameters. Patients with any MR had an excess all-cause mortality that was more 
than eight times that compared to patients with no MR. In addition, increasing severity of MR 
had a progressively negative impact on survival with mild and moderate/severe MR being 
predictors of poor outcome. Mitral regurgitation is common and most patients are 
asymptomatic at diagnosis, which was previously believed to be a benign finding.
26
 However, 
Enriquez-Sarano et al. (2005)
27
 demonstrated that asymptomatic MR is a powerful predictor 
of death from any cause, death from cardiac causes and cardiac events. The management of 
asymptomatic patients with valve disease is an important medical problem
28
 and the results of 
our study suggest that quantitative assessment of MR severity permits risk stratification of 
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patients undergoing EVAR. Recent guidelines on the management of valvular heart disease
29
 
suggest that mitral valve surgery is recommended in patients presenting with asymptomatic 
severe MR with decompensated left or right ventricular function and reasonable in patients 
presenting with asymptomatic severe MR with compensated ventricular function. However, 
in patients with MR present, regular surveillance is necessary since early surgery has been 
shown to have better outcomes compared to conservative approaches.
30
 TTE is recommended 
for the initial evaluation of valvular heart disease
29
 and due to its prognostic power should be 
included as part of the clinical decision making process for patients undergoing elective 
EVAR for AAA. 
 
Disease of the aorta is an important cause of cardiovascular morbidity and mortality. Unless 
complications are life threatening, diseases of the aorta are asymptomatic and concealed on 
physical examination. As such, imaging tools are exclusively relied upon for diagnosis. There 
has been strong support in the literature for studying the abdominal aorta during conventional 
TTE,
31
 with the prevalence of AAA during TTE ranging from 0.43% to 8.8%.
32-38
 Our study 
demonstrated that dimensions of the proximal aorta on TTE, including the aortic sinotubular 
junction, tubular ascending aorta, and aortic arch were significantly different between alive 
versus deceased patients. In adjusted multivariable analysis, the tubular ascending aorta was 
an important independent discriminator of all-cause mortality. Patients with a greater tubular 
ascending aorta had an excess mortality that was more than five times that compared to 
patients with normal dimensions. Current guidelines on the management of patients with 
aortic dilatation have advised on intervention in combination with a bicuspid aortic valve or 
aortic regurgitation.
39
 At present no recommendation exists based on aortic dilatation and MR 
severity. Future research is required to assess if prophylactic intervention to correct aortic 
dilatation and/or MR valve disease prior to EVAR for AAA improves outcome.  
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Previous research evaluating cardiovascular predictors of long-term mortality after EVAR for 
AAA
40
 has failed to identify any TTE parameters as predictors of mortality. Instead, 
Ohrlander et al., (2011) demonstrated that ischemia on electrocardiography (HR 1.6, 95% CI 
1.1-1.4, p=0.02) and anaemia (HR 1.5, 95% CI 1-2.1, p=0.05) were predictors of long-term 
mortality. More recently, any valve disease on TTE was a predictor of 1-year mortality (Odds 
Ratio 3.5, 95% CI 1.2-10.7; p=0.03) in a similar group of patients.
41
 However, in this study 
only visual assessment of valvular heart disease was used, no measures of the aorta were 
noted, and not all patients underwent pre-operative TTE assessment. Other predictors of 
outcome following EVAR for AAA include pre-operative cardiac risk factors, length of 
hospital intensive care stay, ST-segment elevation myocardial infarction,
42
 pre-operative 
aneurysm size,
43
 renal disease,
41
 and reduced statin use.
44, 45
 In our study, these parameters 
were not significantly different between alive and deceased patients.   
 
LVEF was a predictor of outcome. An impaired LV is an established risk factor for early 
cardiovascular morbidity and mortality. Interestingly, previous research has failed to show 
LVEF as a predictor of outcome in patients undergoing EVAR for AAA. However, in 
patients undergoing repair of the thoracic aorta, an impaired LV function was the strongest 
cardiac predictor of mortality (Odds Ratio 1.85, 95% CI 1.09-3.15; p=0.03).
46
 A surprising 
finding in the current study was that younger age was independently associated with all-cause 
mortality. This finding reflects the fact that the youngest patients selected for EVAR are 
typically those with the greatest comorbidity, precluding them from open surgical repair. In 
addition, the presence of diabetes was independently associated with all-cause mortality. 
Diabetes is a recognised co-morbid disease that negatively influences outcome in patients 
with AAA.
11
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Our data support recent AAA guidelines,
11
 which detail that patients considered medium to 
high-risk should be sent for cardiology review in order to examine cardiac risk with a view to 
optimise cardiac function, initiate cardio-protective medication before planned procedures 
and address behavioural CVD risk factors.
47
 It is worth noting that although no significant 
differences existed between groups with regards to medication, use of cardio-protective 
medication was low and optimisation before surgery, such as beta-blockers and angiotensin 
converting enzyme inhibitors may improve outcome particularly in high-risk patients and 
those with heart failure.
48
 In addition, it could be argued that high-risk patients also undergo 
counselling to ensure full comprehension of the risks of surgical intervention, bearing in 
mind that 43% of patients in the high-risk group were deceased at 2-years post-EVAR; it 
might be the case that there is an identifiably high-risk group of patients to whom surgical 
intervention should not be offered. By the same token, the intermediate risk group may 
warrant more aggressive optimisation and follow-up to ensure they experience the maximum 
survival benefit that aneurysm repair offers.  
 
To our knowledge this is the first study that used systematic TTE in the clinical work up of 
patients prior to elective EVAR for AAA, incorporating quantitative measures of valvular 
heart disease and imaging of the aorta in conjunction with standard TTE parameters. This 
study has demonstrated that TTE provides prognostic information independent of traditional 
risk factors and likely serves as a useful test for guiding clinical treatment and management 
of patients.   
 
Our study has limitations. This was a single centre study, which recruited selected patients 
for EVAR for AAA and there is the potential for referral bias. Due to difficulties in 
accurately determining the cause of death by reviewing death certificates or medical records, 
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all-cause mortality was selected as a more objective and unbiased end point. Patients 
recruited in our study had satisfactory pulmonary function and as such we do not have data to 
estimate the prognostic significance of pre-existing pulmonary disease. In addition, we did 
not record intensive care stay post EVAR and are therefore unable to estimate if this had an 
impact on patient outcome in this study. Notwithstanding these limitations, the present study 
extends our knowledge of risk stratification in patients undergoing EVAR for AAA, 
especially in the context of long-term survival. This is all the more important given that peri-
operative and 30-day mortality has improved so significantly in the era of endovascular 
surgery. 
 
Conclusion 
 
Transthoracic echocardiography provides important long-term prognostic information in 
patients undergoing EVAR. These TTE indices were more important at predicting outcome 
than standard conventional risk factors in this patient group and may serve as a useful tool for 
guiding clinical management. A greater tubular ascending aorta, presence of MR, reduced left 
ventricular ejection fraction and younger age were independently associated with long-term 
mortality. 
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Clinical Perspective 
 
Abdominal aortic aneurysms (AAA) remain a significant health challenge and its prevalence 
significantly increases with age. Endovascular aneurysm repair (EVAR) has developed into a 
viable alternative to open surgery for AAA repair. Despite an established benefit in terms of 
peri-operative mortality for EVAR the long-term outcome in patients with AAA remains 
poor. Due to a strong association between traditional cardiovascular disease risk factors and 
higher incidence of AAA, guidelines recommend pre-operative risk stratification of patients. 
As a consequence, a transthoracic echocardiogram (TTE) is often advised as part of the 
clinical assessment of patients awaiting aneurysm repair despite a lack of evidence base. This 
study highlights that within the EVAR population there is a high-risk cohort of patients with 
43% mortality at 2-years post procedure despite a successful endovascular repair. TTE 
provides powerful parameters that can predict long-term outcome in this patient group. The 
results require further prospective study, but suggest a potential role for more aggressive pre-
operative optimisation in higher risk populations. The results may also provide a framework 
for better selection of patients who may benefit long-term from EVAR.  
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Figure Legends 
 
Figure 1: Study flow diagram. 
 
Figure 2: Kaplan-Meier curve for the cumulative survival according to the presence or 
absence of mitral regurgitation. 
 
Figure 3: Kaplan-Meier curve for the cumulative survival according to low, intermediate and 
high-risk. 
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Table 1. Characteristics of Patients Survived versus All-Cause Mortality 
 Survived All-Cause Mortality 
Parameters  (n = 195) (n = 78) 
Demographics   
 Age, y 73 ± 10.3 73.1 ± 11.8 
 Men 159 (81.5) 59 (75.6) 
History    
 Angiogram 28 (14.4) 7 (9) 
 Current Smoker 49 (25.1) 25 (32.1) 
 Diabetes Mellitus 23 (11.8) 11 (14.1) 
 Family History of Cardiovascular Disease 14 (7.2) 5 (6.4) 
 Heart Failure 2 (1) 1 (1.3) 
 Hypercholesterolemia 107 (54.9) 38 (48.7) 
 Hypertension 149 (76.4) 61 (78.2) 
 Prior Cerebrovascular Accident 23 (11.8) 12 (15.4) 
 Prior Coronary Artery Bypass Graft Surgery 1 (0.5) 0 (0) 
 Prior Ischaemic Heart Disease 70 (35.9) 27 (34.6) 
 Prior Myocardial Infarction 8 (4.1) 5 (6.4) 
 Prior PCI  2 (1) 1 (1.3) 
 Prior Smoker 91 (46.7) 35 (44.9) 
Long-term medication   
 All Lipid Lowering Drugs 162 (83.1) 66 (84.6) 
 Angiotensin-Converting Enzyme Inhibitors 52 (26.7) 24 (30.8) 
 Angiotensin II Receptor Antagonist 27 (13.8) 9 (11.5) 
 Antiarrhythmic Agents 12 (6.2) 4 (5.1) 
 Aspirin 128 (65.6) 50 (64.1) 
 Beta Blockers 69 (35.4) 26 (33.3) 
 Calcium antagonists 75 (38.5) 25 (32.1) 
 Diuretic 57 (29.2) 15 (19.2) 
 Nitrates 22 (11.3) 10 (12.8) 
 Wafarin 18 (9.2) 7 (9) 
Laboratory values   
 Hemoglobin (g·dl-1) 12.98 ± 1.9 14.01 ± 14.4 
 White Blood Cell Count (K·ul-1) 8.18 ± 2.9 8.14 ± 2.8 
 Platelet Count (K·ul-1) 253. 8 ± 97.3 262.7 ± 114.8 
 Sodium (mmol·l-1) 137.5 ± 4.3 134.4 ± 20 
 Potassium (mmol·l-1) 4.28 ± 0.4 6.52 ± 15.6 
 Urea (mmol·l-1) 7.35 ± 3.1 8.89 ± 5.3 
 Creatinine (µmol·l-1) 101.9 ± 54.1 124 ± 98.4 
 eGFR (ml·min·1.73m2) 66.4 ± 23.8 62.2 ± 26.3 
 eGFR <45 ml·min·1.73m2 29 (14.9) 16 (20.5) 
 Cardiac Troponin T (µg·l-1) 0.08 ± 0.02 2.29 ± 5.57 
 C-Reactive Protein (nmol·l-1) 50 ± 58.5 67 ± 87.6 
 Glucose (mmol·l-1) 6.2 ± 2.2 6.5 ± 1.6 
 Total Cholesterol (mmol·l-1) 4.14 ± 1.2 4.86 ± 1 
 Low Density Lipoprotein (mmol·l-1) 2.33 ± 0.9 2.98 ± 1.3 
 High Density Lipoprotein (mmol·l-1) 1.21 ± 0.4 1.27 ± 0.5 
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Note: PCI = Percutaneous coronary intervention; eGFR = Estimated glomerular filtration rate (calculated 
according to the Cockroft-Gault formular). 
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Table 2. Echocardiography and Electrocardiography Results of Patients Survived versus All-Cause Mortality 
 Survived All-Cause Mortality 
Parameters  (n=195) (n=78) 
Transthoracic Echocardiography   
 LV End Systolic Diameter (cm) 3.12±0.7 3.42±0.8 
 LV End Diastolic Diameter (cm) 4.85±0.6 5.04±0.7 
 LV Fractional Shortening (%) 36±9.6 32±8.7 
 LV Ejection Fraction (%) 62±10.9 53±9 
 Left Atrial Size (cm) 3.8±0.7 4±0.8 
 IVSd Diastole (cm) 1.06±0.2 1.06±0.2 
 LVPWd Diastole (cm) 1.04±0.2 1.01±0.2 
 LVM (g) 193.5±57.9 201.7±60.1 
 E (m·s-1) 0.65±0.2 0.71±0.3 
 A (m·s-1) 0.81±0.2 0.82±0.2 
 E/A 0.86±0.5 0.9±0.3 
 Pulmonary Artery Pressure (mmHg) 30.3±14.1 36.4±15.1 
 Pulmonary Artery Pressure >35 mmHg 50 (26) 34 (44) 
 Aortic Annulus (cm) 2.39±0.3 2.4±0.3 
 Aortic Sinus of Valsalva (cm) 3.59±0.4 3.59±0.4 
 Aortic Sinotubular Junction (cm) 3.18±0.4 3.4±0.5 
 Tubular Ascending Aorta (cm) 3.35±0.4 3.74±0.6 
 Aortic Arch (cm) 3.09±0.4 3.38±0.5 
 Descending Aorta (cm) 2.55±0.4 2.56±0.4 
 Resting Wall Motion Abnormality 40 (21) 24 (31) 
 Aortic Regurgitation 55 (28) 19 (24) 
 Aortic Stenosis 13 (7) 7 (9) 
 Mitral Regurgitation 70 (36) 67 (86) 
 Mitral Stenosis 4 (2) 1 (1) 
 Tricuspid Regurgitation 41 (21) 17 (22) 
 Pulmonary Regurgitation 16 (8) 6 (8) 
Electrocardiography (ECG)   
 Pathological ECG 46 (24) 23 (30) 
 Ischemic ECG 16 (8) 4 (5) 
Note: LV = Left ventricular; IVSd = Interventricular septal diameter; LVPWd Left ventricular posterior wall 
diameter; LVM = Left ventricular mass;  
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Table 3. Multivariable Predictors of Long-term Mortality  
 Hazard Ratio P 
Predictor  (95% Confidence Interval) Value 
Demographics   
 Age, y 0.97 (0.95-0.99) 0.005 
 Men 1.03 (0.55-1.92) 0.925 
History    
 Diabetes Mellitus 1.46 (1.24-1.89) 0.021 
 Prior Cerebrovascular Accident 2.11 (0.6-7.4) 0.245 
Transthoracic Echocardiography   
 LV Ejection Fraction (%) 0.96 (0.93-0.98) <0.001 
 Pulmonary Artery Pressure >35 mmHg 1.38 (0.81-2.33) 0.234 
 Aortic Sinotubular Junction (cm) 2.18 (0.86-5.54) 0.1 
 Tubular Ascending Aorta (cm) 5.6 (2.77-11.33) <0.001 
 Aortic Arch (cm) 1.1 (0.97-1.14) 0.337 
 Mitral Regurgitation 8.13 (4.09-12.16) <0.001 
Laboratory values   
 eGFR (ml·min·1.73m2) 1.63 (0.62-4.28) 0.319 
Note: Models were selected using forward stepwise selection. Age and gender were forced into all models. LV 
= Left ventricular; eGFR = Estimated glomerular filtration rate (calculated according to the Cockroft-Gault 
formula).  
 
 
